ESSA Pharma Inc. (EPIX): Price and Financial Metrics
EPIX Price/Volume Stats
| Current price | $6.32 | 52-week high | $11.67 |
| Prev. close | $6.72 | 52-week low | $2.56 |
| Day low | $6.18 | Volume | 102,300 |
| Day high | $7.01 | Avg. volume | 138,055 |
| 50-day MA | $8.66 | Dividend yield | N/A |
| 200-day MA | $5.67 | Market Cap | 279.60M |
EPIX Stock Price Chart Interactive Chart >
ESSA Pharma Inc. (EPIX) Company Bio
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor. The company was founded in 2009 and is based in Vancouver, Canada.
Latest EPIX News From Around the Web
Below are the latest news stories about ESSA PHARMA INC that investors may wish to consider to help them evaluate EPIX as an investment opportunity.
These Stocks under $10 Are Poised To ExplodeIn this piece, we will take a look at these stocks under $10 are poised to explode. If you want to skip our introduction to these tricky stocks, jump to These 5 Stocks Under $10 Are Poised To Explode. The US equity markets remain on track for a strong finish in 2023 as major indices […] |
EPIX: Initial Data from Combination Trial of Masofaniten and Enzalutamide Expected in 2024…By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Update on Masofaniten Clinical Programs ESSA Pharma Inc. (NASDAQ:EPIX) is developing masofaniten (EPI-7386), its next-generation antigen molecule that is designed to target the N-terminal domain (NTD) of the androgen receptor (AR) as a treatment for prostate cancer. Masofaniten is currently being evaluated in two |
EPIX Stock Earnings: ESSA Pharma Beats EPS for Q4 2023EPIX stock results show that ESSA Pharma beat analyst estimates for earnings per share the fourth quarter of 2023. |
ESSA Pharma Inc (EPIX) Reports Fiscal Q4 and Full-Year Earnings, Advances in Prostate Cancer ...Corporate Update and Financial Highlights for the Year Ended September 30, 2023 |
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company, focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fourth quarter and fiscal year ended September 30, 2023. |
EPIX Price Returns
| 1-mo | -31.23% |
| 3-mo | -28.02% |
| 6-mo | 61.64% |
| 1-year | 127.34% |
| 3-year | -75.68% |
| 5-year | 166.44% |
| YTD | -4.24% |
| 2023 | 161.90% |
| 2022 | -82.25% |
| 2021 | 19.03% |
| 2020 | 116.91% |
| 2019 | 161.90% |
Loading social stream, please wait...